Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) announced on Wednesday that it has entered into a collaboration with medical data analytics company aimed analytics to leverage AI in drug discovery and optimisation.

This partnership aligns with TME Pharma's strategic plan to enhance its attractiveness to potential strategic partners.

The collaboration aims to accelerate drug development by utilising AI to identify and refine drug candidates, reducing the reliance on time-consuming and resource-intensive laboratory testing. By integrating AI-driven insights into its drug discovery process, TME Pharma seeks to expedite the development of novel therapies for cancer while improving efficiency and reducing costs.

"The goal of this collaboration is to allow TME Pharma to not only bring its existing drugs to the table for strategic partners, but also the potential for rapid and efficient discovery of new drugs," said Aram Mangasarian, CEO of TME Pharma.